- VBL's Phase 2 study in recurrent glioblastoma (rGBM) met the primary endpoint of statistically-significant increase in median overall survival, with 59 weeks in patients treated with continuous exposure of VB-111, compared to 32 weeks in patients with limited VB-111 exposure (p=0.048).
- Median overall survival for patients on continuous exposure of VB-111 was 59 weeks, compared with 32 weeks in historical pooled Avastin trials (p= 0.0295).
- 12-Month overall survival was 57% in patients on continuous exposure of VB-111, compared with 24% in historical pooled Avastin trials (p=0.03).
Catalyst
Slingshot members are tracking this event:
Clinical Data Presented at ASCO Demonstrate Significant Overall Survival Benefit in rGBM Patients Receiving VB-111 Compared with Historical Avastin Meta-analysis Data
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| VBLT |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 03, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Rgbm, Vb-111, Avastin
